Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

  • BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil
    • News

  • Harris Technology eyes profitability as refurbished tech sales surge
    Harris Technology eyes profitability as refurbished tech sales surge
    • News

  • QIC Fund Backs Ark Mines with $4.5m to Accelerate Sandy Mitchell Development
    • News

  • Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    Swift Secures $2.4m Chevron Contract to Extend Entertainment and Support Services
    • News

  • FBR’s tech could help reduce housing construction-related cost pressures
    FBR’s tech could help reduce housing construction-related cost pressures
    • News

  • Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    Atomo Locks in US$410K Pascal Order as FebriDx Demand Accelerates in the US
    • News

  • June 2025 quarter CPI no roadblock to August RBA rate cut
    June 2025 quarter CPI no roadblock to August RBA rate cut
    • News

It’s tryout season for NGS’s sports supplement on kids that want to go pro

  • In News
  • January 11, 2023
  • Alinda Gupta
It’s tryout season for NGS’s sports supplement on kids that want to go pro

Soccer (or football, as some aficionados would leap to correct) is the world’s most-played sport. In fact, its popularity has increased following the FIFA World Cup, which saw millions of people tuning in for every match. The enthusiasm is high and the ambition to become a soccer player even higher, especially when you consider the salaries they make—the likes of Kylian Mbappe and Lionel Messi make upwards of $100 million. 

Perhaps that’s what encouraged children to participate in the nutritional supplement company Nutritional Growth Solutions’ (ASX: NGS) trials. The Company has invested $100k in conducting clinical trials to evaluate the effectiveness of its innovative sports supplement on the physical activity performance of young soccer players. 

Nutritional Growth Solutions CEO and Managing Director, Liron Fendell, shared, “The global sports nutrition market and supplements was valued at US$44.43 billion in 2021 and is expected to increase in value to US$85.7 billion by 2030. Based on extensive research, NGS has formulated an innovative nutritional supplement, aimed at [the] completion of the high nutritional requirements of adolescent athletes to help them improve their body composition, exercise performance and general health.”

The clinical trial will recruit up to 50 healthy soccer players, aged 8 to 15, to determine the efficacy and safety of the new supplement versus placebo. The Company will run multiple tests,  like 10m and 20m sprints, countermovement jumps, agility tests, endurance tests, anthropometric assessments (height, weight and BMI) and body composition, to evaluate effectiveness. 

The NGS innovative nutritional supplement packs a significant dose of energy, comprising high-quality whey proteins, additional specific amino acids, creatine monohydrate, carbohydrates, fats, and micronutrients (including calcium, iron, zinc, magnesium, vitamin A, vitamin C, vitamin D, vitamin E and vitamin B complex). 

If a player is nutrient deficient, they run the risk of losing muscle mass, overall strength and bone mineral density. Research has found that lacking sufficient calories, and macro and micro-nutrients may impair an athlete’s training adaptations. Plus, they are more likely to fall sick. The player might also overtrain to compensate for their poor performance and put a strain on their body. 

To shoot two goals in two minutes like Mbappé did during the FIFA World Cup finals, football players need, well, skill, but also a comprehensive round-up of nutrients. NGS aims to provide that in a supplement. 

Fendell added, “This trial marks our first step into the growing sports supplements market, and we look forward to offering active children a safe, effective supplement, which was designed especially for them.”

In 2023, the Company’s focus will be on boosting US sales of its products. Still, NGS will give due attention to international market expansions (it expanded into Poland just last month) and trials in the coming weeks. 

The clinical trial comprises an eight-week treatment period followed by an eight-week open-label period. Initial results are expected in Q3 2023.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx ngs
  • Liron Fendell
  • mbappe
  • ngs
  • nutritional growth supplements
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.